Faculty Publications

As of August 2017, this database is no longer being updated. For the most current publications from the faculty, students, and staff of Touro University, please check our institutional repository, Touro Scholar, and email any questions or publication submissions to touro.scholar@touro.edu.

Total number of publications: 7,082

Enter a faculty name:

Administrative Offices

Graduate Schools

Health Sciences

Lander Colleges

Law Center

New York School of Career and Applied Studies (NYSCAS)

Touro University System

First Prev 1 2 3 4 5 6 7 8 9 10 Next Last
  • Cohen, K. R., Shinkazh, N., Frank, J., Israel, I., & Fellner, C. (2015). Pharmacological treatment of diabetic peripheral neuropathy. P & T, 40(6), 372, 375-388. This material can be found here.

  • Cohen, K., Ruggiero, R. J., Lauletta, J., Chelenes, J. J., & Shirangi, S. (1998). Examination of pharmacotherapeutic alternatives for the treatment of pain in the emergency department of an inner city teaching hospital. P & T, 23(6).

  • Cope, R., Berkowitz, L., Arcebido, R., Yeh, J. Y., Trustman, N., & Cha, A. (2015). Evaluating the effects of an interdisciplinary practice model with pharmacist collaboration on HIV patient co-morbidities. AIDS Patient Care and STDs, 29(8), 445-453. doi:10.1089/apc.2015.0018

  • Cope, R., Glowa, T., Faulds, S., McMahon, D., & Prasad, R. (2016). Treating hepatitis C in a Ryan White-funded HIV clinic: Has the treatment uptake improved in the interferon-free directly active antiviral era? AIDS Patient Care and STDs, 30(2), 51-55. doi:10.1089/apc.2015.0222

  • Cope, R., Pickering, A., Glowa, T., Faulds, S., Veldkamp, P., & Prasad, R. (2015). Majority of HIV/HCV patients need to switch antiretroviral therapy to accommodate direct acting antivirals. AIDS Patient Care and STDs, 29(7), 379-383. doi:10.1089/apc.2015.0004

  • Cui, Y., Watson, D. J., Girman, C. J., Shapiro, D. R., Gotto, A. M., Hiserote, P., & Clearfield, M. B. (2009). Effects of increasing high-density lipoprotein cholesterol and decreasing low-density lipoprotein cholesterol on the incidence of first acute coronary events (from the Air Force/Texas Coronary Atherosclerosis Prevention Study). American Journal of Cardiology, 104(6), 829-834. This material can be found here.

  • D'Alonzo, G. E., Smolensky, M. H., Feldman, S., Gianotti, L. A., Emerson, M. B., Staudinger, H., & Steinijans, V. W. (1990, July). Twenty-four hour lung function in adult patients with asthma: Chronoptimized theophylline therapy once-daily dosing in the evening versus conventional twice-daily dosing. American Review of Respiratory Disease, 142(1), 84-90.

  • D'Alonzo, G. E., Smolensky, M. H., Feldman, S., Gnosspelius, Y., & Karlsson, K. (1995, February). Bambuterol in the treatment of asthma: A placebo-controlled comparison of once-daily morning vs evening administration. Chest, 107(2), 406-412.

  • D'Souza, R. W., Bruckner, J. V., & Feldman, S. (1985). Oral and intravenous trichloroethylene pharmacokinetics in the rat. Journal of Toxicology and Environmental Health, 15(5), 587-601.

  • Dager, W. E. (2009). Dosing nomograms: Silos on a slope [editorial]. Annals of Pharmacotherapy, 43(1), 114-117. This material can be found here.

  • Dager, W. E. (2010). Issues in assessing and reducing the risk for venous thromboembolism. American Journal of Health-System Pharmacy, 67(10 Suppl. 6), S9-16. doi:10.2146/ajhp100177

  • Dager, W. E. (2012). Warfarin for venous thromboembolism prophylaxis after elective hip or knee arthroplasty: Exploring the evidence, guidelines, and challenges remaining. The Annals of Pharmacotherapy, 46(1), 79-88. doi:10.1345/aph.1P626

  • Dager, W. E. (2013). Developing a management plan for oral anticoagulant reversal. American Journal of Health-System Pharmacy, 70(10), S21-S31. This material can be found here.

  • Dager, W. E., & Banares, L. (2017). Reversing the anticoagulation effects of dabigatran. Hospital Practice, 45(2), 29-38. This material can be found here.

  • Dager, W. E., & Halilovic, J. (2014). Acute kidney injury. In J. T. DiPiro, R. L. Talbert, G. C. Yee, G. R. Matzke, B. G. Wells, & L. M. Posey (Eds.), Pharmacotherapy: A pathophysiologic approach (9th ed., pp. 611-632). New York, NY: McGraw-Hill Medical.

  • Dager, W. E., & Kiser, T. H. (2010). Systemic anticoagulation considerations in chronic kidney disease. Advances in Chronic Kidney Disease, 17(5), 420-427. doi:10.1053/j.ackd.2010.06.002

  • Dager, W. E., & Roberts, A. J. (2016). Prevention and treatment of venous thromboembolism. In B. L. Erstad (Ed.), Critical care pharmacotherapy (pp. 449-467). Lenexa, KS: American College of Clinical Pharmacy.

  • Dager, W. E., Gosselin, R. C., Kitchen, S., & Dwyre, D. (2012). Dabigatran effects on the international normalized ratio, activated partial thromboplastin time, thrombin time, and fibrinogen: A multicenter, in vitro study. The Annals of Pharmacotherapy, 46(12), 1627-1636.  doi:10.1345/aph.1R179 

  • Dager, W. E., Gulseth, M. P., & Nutescu, E. A. (2010). Anticoagulation therapy: A point of care guide. Bethesda, MD: American Society of Health-System Pharmacists.

  • Dager, W. E., Shulman, R., & Jacobi, J. (2010). Preparation and training of critical care pharmacists. In H. Flaatten, R. P. Moreno, C. Putensen, & A. Rhodes, (Eds.), Organisation and management of intensive care (pp. 133-142). Berlin, Germany: Medical Scientific Publishing GmbH & Co. This material can be found here.

  • Dallas, C. E., Weir, F. W., Feldman, S., Putcha, L., & Bruckner, J. V. (1983, March). Uptake and disposition of 1,1-dichloroethylene in rats during inhalation exposure. Toxicology and Applied Pharmacology, 68(1), 140-151.

  • Daniels, B. H., McComb, R. D., Mobley, B. C., Gultekin, S. H., Lee, H. S., & Margeta, M. (2013). LC3 and p62 as diagnostic markers of drug-induced autophagic vacuolar cardiomyopathy: A study of 3 cases. American Journal of Surgical Pathology, 37(7), 1014-1021. doi:10.1097/PAS.0b013e3182863fa8

  • Del Bello, D., Cha, A., Sorbera, M. A., Bichoupan, K., Levine, C., Doyle, E., . . . Branch, A. D. (2016). Real-world sustained virologic response rates of sofosbuvir-containing regimens in patients coinfected with hepatitis C and HIV. Clinical Infectious Diseases, 62(12), 1497-1504. doi:10.1093/cid/ciw119

  • Del Rosso, J.Q., & Kircik, L. H. (2013). The role of a midpotency topical corticosteroid and the clinical relevance of formulation characteristics in the management of commonly encountered eczematous and inflammatory dermatoses in adults and children: Focus on the pharmacologic properties of clocortolone pivalate 0.1% cream. Journal of Drugs in Dermatology, 12(2), s5-s10.

  • Del Rosso, J. Q., & Tanghetti, E. (2013). A status report on topical tazarotene in the management of acne vulgaris [Supplemental material]. Journal of Drugs in Dermatology, 12(3), s53-s58. This material can be found here.

First Prev 1 2 3 4 5 6 7 8 9 10 Next Last